Correspondence 0001683168-23-004087 from Z Squared Inc. (COEP)
Z Squared Inc.
Date: June 12, 2023 · CIK: 0001759186 · Accession: 0001683168-23-004087
AI Filing Summary & Sentiment
File numbers found in text: 333-260782
Letter
Re: Coeptis Therapeutics Holdings, Inc.
June 12, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Timothy Buchmiller
Registration Statement on Form S-1
File No. 333-260782
Ladies and Gentlemen:
As representative of the underwriters of the proposed public offering of securities of Coeptis Therapeutics Holdings, Inc. (the “Company”), we hereby join the Company’s request that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will be declared effective at 5:30 p.m., Eastern Time, on Tuesday, June 13, 2023, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as representative of the underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that it has complied and will continue to comply, and that it has been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
Very truly yours,
Ladenburg Thalmann & Co. Inc.
Show Raw Text
CORRESP
1
filename1.htm
June 12, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Timothy Buchmiller
Re:
Coeptis Therapeutics Holdings, Inc.
Registration Statement on Form S-1
File No. 333-260782
Ladies and Gentlemen:
As representative of the underwriters
of the proposed public offering of securities of Coeptis Therapeutics Holdings, Inc. (the “Company”), we hereby join
the Company’s request that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that
it will be declared effective at 5:30 p.m., Eastern Time, on Tuesday, June 13, 2023, or at such later time as the Company or its counsel
may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under
the Act, we, as representative of the underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who
is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus
as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that
it has complied and will continue to comply, and that it has been informed by the participating underwriters and dealers that they have
complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
1
Very truly yours,
Ladenburg Thalmann & Co. Inc.
By: /s/ Nicholas Stergis
Name: Nicholas Stergis
Title: Managing Director
cc:
David Mehalick, Coeptis Therapeutics Holdings, Inc.
Richard A. Friedman, Sheppard, Mullin, Richter
& Hampton LLP
Denis Dufrense, Esq. Meister Seeling & Fein
PLLC
2